1. Haruma K, Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003;18 Suppl 1:153–9.
2. Ishihara T, Tanaka KI, Tashiro S, Yoshida K, Mizushima T. Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis. Biochem Pharmacol. 2010;79(11):1622–33. http://dx.doi.org/10.1016/j.bcp.2010.01.030
3. Lee S, Jeong S, Kim W, Kim D, Yang Y, Yoon JH, et al. Rebamipide induces the gastric mucosal protective factor, cyclooxygenase-2, via activation of 5′-AMP-activated protein kinase. Biochem Biophys Res Commun. 2017;483(1):449–55. http://dx.doi.org/10.1016/j.bbrc.2016.12.123
4. Surdea-Blaga T, Băncilă I, Dobru D, Drug V, Frățilă O, Goldiș A, et al. Mucosal protective compounds in the treatment of gastroesophageal reflux disease. A position paper based on evidence of the Romanian society of neurogastroenterology. J Gastrointest Liver Dis. 2016;25(4):537–46.
5. Haruma K, Ito M, Kido S, Manabe N, Kitadai Y, Sumii M, et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862–7.
6. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(i):20–4. http://doi.wiley.com/10.1111/jgh.12769
7. Savarino E, Zentilin P, Marabotto E, Pellegatta G, Coppo C, Brunacci M, et al. Drugs for improving esophageal mucosa defense: Where are we now and where are we going? Ann Gastroenterol. 2017;30(6):585–91.
8. Tran T, Lowry AM, El-Serag HB. Meta-analysis: The efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther. 2007;25(2):143–53.
9. Holtmeier W, Holtmann G, Caspary WF, Weingärtner U. On-demand Treatment of Acute Heartburn With the Antacid Hydrotalcite Compared With Famotidine and Placebo. J Clin Gastroenterol. 2007 Jul;41(6):564–70. https://insights.ovid.com/crossref?an=00004836-200707000-00005
10. Xiao YL, Nie YQ, Hou XH, Xie PY, Fang JY, Yuan YZ, et al. The efficacy, safety and cost-effectiveness of hydrotalcite versus esomeprazole in on-demand therapy of NERD: A multicenter, randomized, open-label study in China. J Dig Dis. 2013 Sep;14(9):463–8. http://doi.wiley.com/10.1111/1751-2980.12069
11. Manabe N, Haruma K, Ito M, Takahashi N, Takasugi H, Wada Y, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: A randomized clinical trial. Dis Esophagus. 2012;25(5):373–80.
12. Reimer C, Lødrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial: Alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899–909.
13. Katz PO. Editorial: refractory GERD-good drug, wrong patients? Aliment Pharmacol Ther. 2017 Jul;46(2):203–4. http://doi.wiley.com/10.1111/apt.14120
14. Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N. An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci. 2008;53(11):2896–903.
15. Katz PO, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2013 Mar 19;108(3):308–28. http://dx.doi.org/10.1038/ajg.2012.444